OncoMatch/Clinical Trials/NCT07668869
TTFields Plus FET-PET-Guided Stereotactic Radiosurgery Versus TTFields Alone for Recurrent Glioblastoma (Tarrget 2.0)
Is NCT07668869 recruiting? Yes, currently enrolling (Jul 2026). This NA trial studies Tumor Treating Fields (TTFields) for glioblastoma.
Treatment: Tumor Treating Fields (TTFields) — This study evaluates whether the addition of FET-PET-guided stereotactic radiosurgery (SRS) to Tumor Treating Fields (TTFields) improves survival outcomes in patients with recurrent IDH-wildtype glioblastoma. Patients with recurrent glioblastoma have limited treatment options and poor prognosis. TTFields is a non-invasive antimitotic therapy that has demonstrated efficacy in recurrent glioblastoma. Stereotactic radiosurgery is commonly used in selected patients with recurrent disease; however, treatment efficacy may be limited by the infiltrative nature of glioblastoma and challenges in accurate target delineation. The study hypothesizes that combining TTFields with FET-PET-guided stereotactic radiosurgery will improve one-year overall survival compared with TTFields alone. Participants will be randomized in a 1:1 ratio to receive either TTFields plus stereotactic radiosurgery or TTFields alone.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 wild-type
Histologically confirmed IDH-wildtype glioblastoma
Required: IDH2 wild-type
Histologically confirmed IDH-wildtype glioblastoma
Required: MGMT any tested (testing required; no eligibility threshold specified)
Available molecular profile including IDH and MGMT status
Prior therapy
Must have received: radiation therapy
Prior radiotherapy
Must have received: alkylating agent (temozolomide)
Prior temozolomide treatment
Cannot have received: anti-VEGF therapy (bevacizumab)
Previous bevacizumab treatment
Cannot have received: stereotactic re-irradiation
Exception: within the planned treatment field
Previous stereotactic re-irradiation within the planned treatment field
Lab requirements
Blood counts
adequate hematologic function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07668869 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-VEGF therapy, stereotactic re-irradiation disqualifies patients from enrollment.
Does this trial require IDH1?
Yes, IDH1 wild-type is a required biomarker for enrollment.
Does this trial require IDH2?
Yes, IDH2 wild-type is a required biomarker for enrollment.
Does this trial require MGMT?
Yes, MGMT any tested is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages